Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).

Mitsudomi, Tetsuya; Morita, Satoshi; Yatabe, Yasushi; Negoro, Shunichi; Okamoto, Isamu; Seto, Takashi; Satouchi, Miyako; Tada, Hirohito; Hirashima, Tomonori; Asami, Kazuhiro; Katakami, Nobuyuki; Takada, Minoru; Yoshioka, Hiroshige; Shibata, Kazuhiko; Kudoh, Shinzoh; Shimizu, Eiji; Saito, Hiroshi; Toyooka, Shinichi; Nakagawa, Kazuhiko; Fukuoka, Masahiro; Japan Oncology Group, West

doi:10.1200/jco.2012.30.15_suppl.7521

Public

Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).

Published in Journal of Clinical Oncology • May 20, 2012

Authors:

Tetsuya Mitsudomi

Satoshi Morita

Yasushi Yatabe

Abstract

7521 Background: WJTOG3405 met its primary endpoint of progression free survival (PFS) (9.2 months (mo.) for G vs. 6.3 mo. for CD, hazard ratio (HR) 0.489, 95% confidence interval (CI): 0.336-0.710). (Mitsudomi et al., Lancet Oncol., 2010). However, the impact on overall survival (OS) was not clear ...

View

Paywalled

Subject

Medicine

Hazard ratio

Internal medicine

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Subject

Generate AI Take for this paper

Discussions